Clinical Trial Update: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating first-line Tarlatamab combined with Carboplatin, Etoposide, and a PD-L1 inhibitor for extensive-stage small cell lung cancer; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)
• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING